ASTRO guideline maps radiation therapy roles in bladder cancer

The American Society for Radiation Oncology (ASTRO) has issued its first clinical practice guideline focused specifically on radiation therapy across bladder cancer care. Developed by a multidisciplinary task force and published in Practical Radiation Oncology, the guideline recommends trimodal therapy as a curative alternative to radical cystectomy for appropriately selected patients with muscle-invasive bladder cancer. It also provides recommendations for radiation therapy after surgery, treatment of advanced disease, symptom relief, treatment planning and follow-up. The document is intended to guide individualized decisions by multidisciplinary teams rather than prescribe one approach for every patient.

For appropriately selected patients with cT2-4aN0M0 muscle-invasive bladder cancer, the guideline recommends trimodal therapy as an alternative to radical cystectomy. The approach combines maximal transurethral resection of the bladder tumor, radiation therapy and concurrent radiosensitizing systemic therapy. Favorable features include a solitary tumor smaller than 7 centimeters, predominant urothelial carcinoma and no extensive carcinoma in situ or hydronephrosis. Long-term studies and observational comparisons cited by the guideline suggest that carefully selected patients receiving trimodal therapy can achieve cancer outcomes similar to those seen with radical cystectomy, with the potential to retain a functioning bladder.

Radical cystectomy, the surgical removal of the bladder, has long been a standard curative treatment for muscle-invasive bladder cancer and is typically combined with systemic therapy. The operation requires creating a new route for urine to leave the body. The guideline notes that cystectomy may not be appropriate for some people because of frailty or other health conditions, while others may prefer to preserve their bladder. Task force chair Jason A. Efstathiou said bladder preservation should be presented as a curative treatment option alongside radical cystectomy for appropriately selected patients, with decisions guided by disease characteristics, overall health and personal priorities.

The bladder-preservation recommendations connect several stages of care rather than treating radiation therapy as an isolated intervention. Neoadjuvant or induction systemic therapy is recommended for patients at higher risk of developing metastases. Trimodal therapy should include maximal transurethral resection followed by radiation therapy with concurrent radiosensitizing systemic therapy. After treatment, patients should undergo cystoscopic assessment and continued surveillance for recurrence. The guideline encourages multidisciplinary evaluation and shared decision-making throughout care, with treatment selection and delivery tailored to the patient’s disease, health and preferences.

After cystectomy, adjuvant radiation therapy is conditionally recommended to improve locoregional control for patients at higher risk of recurrence. The higher-risk groups include those with pT3-4 disease, involved lymph nodes or positive surgical margins. The presence of a neobladder does not preclude postoperative radiation therapy. When postoperative radiation is used, treatment generally should begin after adequate surgical recovery and completion of any planned adjuvant chemotherapy. Treatment typically includes the cystectomy bed and pelvic lymph nodes, with modifications for selected patients based on surgical margins, urinary reconstruction and risk of bowel toxicity.

For advanced and symptomatic disease, bladder-directed radiation therapy is recommended to control disease or relieve symptoms such as bleeding and pain in patients with symptomatic metastatic disease and in patients with localized or locoregional disease who are not receiving curative treatment. In patients with low-burden metastatic disease that responds to systemic therapy, radiation therapy directed at the bladder is conditionally recommended. Radiation directed at a limited number of metastatic sites may also be considered. Bladder radiation is not recommended for asymptomatic patients with high-burden metastatic disease, while palliative radiation is recommended for metastatic sites that are symptomatic or likely to cause symptoms.

The guideline provides technical direction for curative and palliative treatment, including dose and fractionation schedules. It also addresses when the whole bladder should be treated, when the tumor should receive a boost and when pelvic lymph nodes should be included. Intensity-modulated radiation therapy with daily image guidance is recommended. The recommendations distinguish postoperative radiation, bladder-directed treatment for advanced or symptomatic disease and radiation directed at selected metastatic sites. They are intended to support treatment planning across these different clinical scenarios while leaving room for individualized assessment and clinical judgment.

The recommendations were developed by a task force of radiation, medical and urologic oncologists, a medical physicist and a patient representative. ASTRO developed the guideline in collaboration with the American Society of Clinical Oncology, the European Association of Urology and the European Society for Radiotherapy and Oncology, and the European Association of Urology endorsed it. The evidence base came from a systematic review of research published from 2009 through 2024. As a clinical practice guideline, the document synthesizes existing evidence to support informed, individualized decisions by physicians and patients rather than establishing a mandatory course of treatment.

Bladder cancer remains a substantial public health concern even though its incidence in the United States has declined modestly over the past decade. It is the fifth most commonly diagnosed cancer among U.S. men and occurs about four times more often in men than in women. The guideline release estimated that 85,000 U.S. adults would be diagnosed with bladder cancer in 2026 and approximately 18,000 would die from the disease. The task force identified persistent disparities in bladder cancer care, noting that access to multidisciplinary evaluation and bladder-preserving treatment may be limited in underserved and rural communities.

To address those gaps, the task force called for broader access to evidence-based treatment and greater inclusion of populations historically underrepresented in bladder cancer research. The guideline maps radiation therapy across the disease course, from curative bladder preservation and postoperative locoregional control to treatment of advanced or symptomatic disease and palliation. ASTRO presented the recommendations as tools for individualized shared decision-making, not as rules that supersede the informed judgments of individual physicians and patients. The scope is limited to recommendations based on the guideline’s systematic review and the evidence available for these treatment settings.

Subject of Research: Clinical guideline for radiation therapy in muscle-invasive and advanced bladder cancer

Article Title: ASTRO issues its first clinical guideline on radiation therapy for bladder cancer

Article References: ASTRO issues its first clinical guideline on radiation therapy for bladder cancer. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: bladder cancer, radiation therapy, trimodal therapy, muscle-invasive cancer, radical cystectomy, adjuvant radiotherapy, palliative care, ASTRO, clinical guidelines, issues, first, clinical